Compare TWST & SHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWST | SHC |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 5.0B |
| IPO Year | 2018 | 2020 |
| Metric | TWST | SHC |
|---|---|---|
| Price | $91.19 | $17.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $46.88 | $20.33 |
| AVG Volume (30 Days) | 1.5M | ★ 2.8M |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 63.89 | ★ 68.75 |
| EPS | N/A | ★ 0.09 |
| Revenue | $376,572,000.00 | ★ $1,163,617,000.00 |
| Revenue This Year | $18.91 | $7.51 |
| Revenue Next Year | $15.07 | $6.00 |
| P/E Ratio | ★ N/A | $194.33 |
| Revenue Growth | ★ 20.32 | 5.74 |
| 52 Week Low | $23.30 | $11.00 |
| 52 Week High | $105.47 | $19.85 |
| Indicator | TWST | SHC |
|---|---|---|
| Relative Strength Index (RSI) | 52.65 | 54.45 |
| Support Level | $86.30 | $15.11 |
| Resistance Level | $105.47 | $17.80 |
| Average True Range (ATR) | 6.31 | 0.52 |
| MACD | -1.21 | -0.13 |
| Stochastic Oscillator | 38.28 | 46.80 |
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.